ArticleCancer chemotherapy and pharmacology2026
Birinapant enhances cisplatin sensitivity in epithelial ovarian cancer through modulation of apoptotic and survival signaling pathways.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundResistance to platinum-based chemotherapy in epithelial ovarian cancer is frequently driven by dysregulation of apoptotic pathways and overexpression of inhibitor of apoptosis proteins (IAPs). Smac mimetics, such as Birinapant, target IAPs and modulate TNF-α-associated signaling; however, their therapeutic efficacy is highly context-dependent.
methodsWe investigated the effects of Birinapant in combination with Cisplatin in ovarian cancer cell lines with distinct sensitivity profiles (SKOV3 and MDAH-2774), along with normal human endometrial stromal cells (HESC) to assess selectivity. Cell viability was measured using the MTT assay, and drug interactions were evaluated using the Chou-Talalay method. Apoptosis was quantified by Annexin V/PI flow cytometry. Protein expression (cIAP1, NF-κB, Caspase-3/8) was analyzed by immunofluorescence, and gene expression (BIRC2, CASP3/8, RELA, TNF) was assessed by RT-qPCR.
resultsThe Birinapant-Cisplatin combination significantly reduced cell viability in SKOV3 cells and demonstrated strong synergistic effects (CI = 0.057-0.237), accompanied by substantial dose reduction. In contrast, MDAH-2774 cells exhibited limited responsiveness and predominantly antagonistic interactions. Mechanistically, combination treatment in SKOV3 cells was associated with reduced cIAP1 expression, suppression of NF-κB signaling, and activation of Caspase-8 and Caspase-3. Notably, TNF Mrna expression was strongly increased (log₂FC ≈ + 5.6), supporting involvement of TNF-associated apoptotic signaling.
conclusionBirinapant increased the sensitivity of SKOV3 ovarian cancer cells to cisplatin by enhancing TNF-α-associated apoptotic signaling, while this synergistic effect was not observed in MDAH-2774 cells, emphasizing the importance of cellular context in determining SMAC mimetic responses. Our findings suggest that TNF-α responsiveness, cIAP1 (BIRC2)-related signaling, and the ability of cancer cells to activate apoptotic pathways, particularly caspase-8, may serve as potential biomarkers for identifying tumors more likely to respond to Birinapant-based combination therapies. Further studies using additional ovarian cancer models and clinical samples are required to validate the predictive value of these biomarkers.
Indexed as
Identifiers
42709209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.